- Home
- NMS vs ELUT Comparison
NMS vs ELUT Comparison
Compare NMS & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- ELUT
- Stock Information
- Founded
- NMS 1993
- ELUT 2015
- Country
- NMS United States
- ELUT United States
- Employees
- NMS N/A
- ELUT N/A
- Industry
- NMS Finance Companies
- ELUT Medical Specialities
- Sector
- NMS Finance
- ELUT Health Care
- Exchange
- NMS Nasdaq
- ELUT Nasdaq
- Market Cap
- NMS 66.4M
- ELUT 71.5M
- IPO Year
- NMS N/A
- ELUT 2020
- Fundamental
- Price
- NMS $11.37
- ELUT $2.38
- Analyst Decision
- NMS
- ELUT Strong Buy
- Analyst Count
- NMS 0
- ELUT 2
- Target Price
- NMS N/A
- ELUT $8.00
- AVG Volume (30 Days)
- NMS 12.0K
- ELUT 26.4K
- Earning Date
- NMS 01-01-0001
- ELUT 08-06-2025
- Dividend Yield
- NMS 4.11%
- ELUT N/A
- EPS Growth
- NMS N/A
- ELUT N/A
- EPS
- NMS N/A
- ELUT N/A
- Revenue
- NMS N/A
- ELUT $23,711,000.00
- Revenue This Year
- NMS N/A
- ELUT $20.10
- Revenue Next Year
- NMS N/A
- ELUT $85.89
- P/E Ratio
- NMS N/A
- ELUT N/A
- Revenue Growth
- NMS N/A
- ELUT N/A
- 52 Week Low
- NMS $9.21
- ELUT $1.61
- 52 Week High
- NMS $12.18
- ELUT $5.12
- Technical
- Relative Strength Index (RSI)
- NMS 44.41
- ELUT 69.40
- Support Level
- NMS $11.30
- ELUT $2.08
- Resistance Level
- NMS $11.45
- ELUT $2.23
- Average True Range (ATR)
- NMS 0.08
- ELUT 0.19
- MACD
- NMS 0.01
- ELUT 0.07
- Stochastic Oscillator
- NMS 55.56
- ELUT 81.52
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.